Marker Therapeutics (MRKR) Accumulated Depreciation (2019)

Marker Therapeutics (MRKR) reported Accumulated Depreciation of $105000.0 for Q4 2019, up 47.89% quarter-over-quarter from $71000.0 in Q3 2019.

Marker Therapeutics (MRKR) Accumulated Depreciation (2019) Analysis & Trends

Marker Therapeutics (MRKR) has 1 years of Accumulated Depreciation data on file, last reported at $105000.0 in Q4 2019.

Accumulated Depreciation for Q4 2019 came in at $105000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $105000.0 (changed N/A YoY), and the FY2019 annual result was $105000.0, changed N/A from the prior year.
Accumulated Depreciation rose to $105000.0 in Q4 2019 per MRKR's latest filing, from $71000.0 in the prior quarter.
Over five years, Accumulated Depreciation peaked at $105000.0 in Q4 2019 and troughed at $40000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Marker Therapeutics	28.20 Mn	28.20 Mn	-

Download Data